Summary of Study ST000455

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000351. The data can be accessed directly via it's Project DOI: 10.21228/M8PC8X This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Download binned data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST000455
Study TitleUtilizing Metabolomics to Understand Novel Anti-Desmoid Tumor Drugs (part II)
Study SummaryThis pilot study will use broad spectrum metabolomics to study the tumorigenesis process of fibroblasts to desmoids by investigating paired desmoid and fibroblast cell lines, in addition to unaffected fibroblast cells. Additionally, this pilot study will explore the effects of two of the active drugs identified on the desmoid and fibroblast cells.
RTI International
Last NameMercier
First NameKelly
Address3040 E. Cornwallis Road
Submit Date2016-08-31
Raw Data AvailableYes
Raw Data File Type(s)1r
Analysis Type DetailNMR
Release Date2017-12-06
Release Version1
Kelly Mercier Kelly Mercier application/zip

Select appropriate tab below to view additional metadata details:


Treatment ID:TR000490
Treatment Summary:Primary cell cultures of desmoid tumor samples were established as previously described [1,2]. Monolayer cell cultures were grown in DMEM supplemented with 5% fetal bovine serum and maintained at 37°C in 5% CO2. Cells were divided when confluent and experiments were performed between the third and sixth passages. Approximately 10 x 106 cells were treated with 1.0uM Dasatinib (Selleck, Houston, USA) dissolved in DMSO, or 0.5uM FAK Inhibitor 14 (Cayman Chemicals Company, Michigan, USA) dissolved in water. Cells were incubated in fresh media containing the inhibitors, or vehicle, for 24 hours.